Ticker Launch
Sign inGet notified

SPAC · Merger completed

Health Sciences Acquisitions Corp

Business combination with Immunovant Sciences Ltd.

Health Sciences Acquisitions Corp is a blank-check company (SPAC) that raised $100M in its initial public offering on May 10, 2019, listing on Nasdaq Capital Market. It completed its business combination with Immunovant Sciences Ltd. on Dec 18, 2019; the combined company is Immunovant, Inc. (IMVT). Morgan Stanley led the IPO, with Chardan and UBS. Loeb & Loeb advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

Immunovant Sciences Ltd., a member of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. It is the target of a business combination with Health Sciences Acquisitions Corporation.

Status
Merger completed
IPO date
May 10, 2019
IPO size
$100M
IPO exchange
Nasdaq Capital Market
Target
Immunovant Sciences Ltd.
Announced
Oct 2, 2019
Stated deal value
$556M
Closed
Dec 18, 2019
Combined company
Immunovant, Inc. (IMVT)
IPO underwriters
Morgan Stanley, Chardan and UBS
SPAC counsel (IPO)
Loeb & Loeb
Underwriters' counsel (IPO)
Kirkland & Ellis

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Get notified at launchOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2019